Lupin Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

The Latest Trading Price of Lupin Ltd is ₹ 2459 as of 07 May 15:30 . The P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 yearsThe P/E Ratio of Sanjivani Paranteral Ltd changed from 28.4 on March 2024 to 35.2 on March 2025 . This represents a CAGR of 11.33% over 2 years The Market Cap of Lupin Ltd changed from ₹ 46318 crore on March 2021 to ₹ 92522 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Sanjivani Paranteral Ltd changed from ₹ 175.32 crore on March 2024 to ₹ 284.8 crore on March 2025 . This represents a CAGR of 27.45% over 2 years The revenue of Lupin Ltd for the Dec '25 is ₹ 7282 crore as compare to the Sep '25 revenue of ₹ 7137 crore. This represent the growth of 2.03% The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The ebitda of Lupin Ltd for the Dec '25 is ₹ 1949 crore as compare to the Sep '25 ebitda of ₹ 2431 crore. This represent the decline of -19.8% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The net profit of Lupin Ltd changed from ₹ 805.54 crore to ₹ 1180 crore over 7 quarters. This represents a CAGR of 24.41% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 32.01% The Dividend Payout of Lupin Ltd changed from 23.43 % on March 2021 to 13.79 % on March 2025 . This represents a CAGR of -10.06% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Lupin Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Lupin Ltd or Sanjivani Paranteral Ltd?

Market cap of Lupin Ltd is 112,463 Cr while Market cap of Sanjivani Paranteral Ltd is 203 Cr

What are the key factors driving the stock performance of Lupin Ltd and Sanjivani Paranteral Ltd?

The stock performance of Lupin Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lupin Ltd and Sanjivani Paranteral Ltd?

As of May 7, 2026, the Lupin Ltd stock price is INR ₹2459.75. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹165.35.

How do dividend payouts of Lupin Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Lupin Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.